Cerulean Pharma reported $45.57M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agile Therapeutics AGRX:US $ 14.74M 11.38M
Arrowhead Research ARWR:US $ 184.43M 141.55M
Bayer BAYN:GR € 4316M 927M
Brainstorm Cell Therapeutics BCLI:US $ 25.7M 4.87M
Cerulean Pharma CERU:US $ 45.57M 36.46M
Immunogen IMGN:US $ 245.76M 6.22M
Macrogenics MGNX:US $ 190.53M 1.56M
Nektar Therapeutics NKTR:US $ 54.02M 98.33M
Perrigo Ordinary Shares PRGO:US $ 2078.1M 1760.6M
Seattle Genetics SGEN:US $ 685.17M 271.74M
YTE INCY:US $ 1999.02M 201.44M